{"id":916725,"date":"2025-12-05T07:23:27","date_gmt":"2025-12-05T12:23:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/peer-reviewed-study-highlights-therapeutic-potential-around-application-of-stromal-cell-therapies-such-as-inmune-bios-cordstrom-platform\/"},"modified":"2025-12-05T07:23:27","modified_gmt":"2025-12-05T12:23:27","slug":"peer-reviewed-study-highlights-therapeutic-potential-around-application-of-stromal-cell-therapies-such-as-inmune-bios-cordstrom-platform","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/peer-reviewed-study-highlights-therapeutic-potential-around-application-of-stromal-cell-therapies-such-as-inmune-bios-cordstrom-platform\/","title":{"rendered":"Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio\u2019s CORDStrom\u2122 Platform"},"content":{"rendered":"
\n

Boca Raton, FL, Dec. 05, 2025 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (\u201cINmune\u201d or the \u201cCompany\u201d), a clinical-stage inflammation and immunology company, announces a recently published overview of future applications and research areas for mesenchymal stromal cell (MSC) therapies, such as INmune\u2019s CORDStrom\u2122 platform. The article, titled, \u201cFate and Function of Exogenously Administered MSCs: Current Insights and Future Directions,\u201d was published in the peer-reviewed journal\u00a0Cytotherapy<\/i>. One of the lead authors of the paper was INmune Bio\u2019s lead scientist for CORDStrom\u2122 R&D, Dr Nikita M. Patel, M.Sci.,Ph.D.<\/p>\n

The article, was the result of an invitation-only working party of basic, clinical and translational scientists working on MSCs and available on Cytotherapy\u2019s website<\/a>, reviews the current knowledge-base and critical gaps in order to formulate experimental questions designed to enhance development of MSC therapies such as the CORDStrom\u2122 platform. These topics included systemic delivery of MSCs, local and\/or depot-delivery (which is the method for the Company\u2019s CORDStrom\u2122 platform), and in vivo persistence.<\/p>\n

\u201cWhile CORDStrom\u2122 is initially being developed for use in RDEB, in which we expect to file a BLA and MAA in 2026, publications such as this one provide important scientific background for future development of the CORDStrom\u2122 platform. Stromal cell therapies are an important clinical advancement that may have significant impact in multiple indications including inflammation, immunomodulation, and wound healing,\u201d said Dr. Mark Lowdell, INmune Bio CSO. \u201cNikita\u2019s role within INmuneBio supports continued advancement in the knowledge base on MSCs. We believe her contributions as one of the senior authors to this article, and the insightful questions asked by the panel, will have an important impact on the development of the use of MSCs in general in addition to the ongoing development of our CORDStrom\u2122 platform.\u201d \u00a0<\/p>\n

\n About CORDStrom\u2122<\/b>\n <\/p>\n

CORDStrom\u2122 (pobistrocel) is a patent-pending cell medicine comprising aseptic, allogeneic, pooled human umbilical cord-derived mesenchymal stromal cells (hucMSCs) in suspension for injection or infusion. The CORDStrom\u2122 platform leverages, among other things, proprietary screening, pooling and expansion techniques to create off-the-shelf, allogeneic, pooled hucMSCs as medicines to treat complex inflammatory, degenerative and autoimmune diseases. CORDStrom\u2122 products are designed to provide high-quality, off-the-shelf, batch-to-batch consistent, scalable, cGMP manufactured, potent cellular medicines that can be produced affordably and with repeatable specification, independent of donor characteristics. While the first generation CORDStrom\u2122 product is agnostic to disease indication, the platform enables creation of indication-specific products, which can be tuned for optimization of anti-inflammatory, immunomodulatory, wound healing, and other characteristics.<\/p>\n

\n About INmune Bio Inc.<\/b>\n <\/p>\n

INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune dysfunction to fight disease. The Company\u2019s pipeline include:<\/p>\n